GOLDEN, Colo.--(BUSINESS WIRE)--Results of a comprehensive review of published scientific literature comparing data associated with various DNA vaccine delivery methods will be presented at the World Vaccine Congress 2023 on April 5, 2023 at 5:10 pm ET.
The presentation will be the first such in-depth comparison and public discussion of existing DNA vaccine administration modalities and their inherent benefits and challenges in the COVID-19 era.
Titled, Improved vaccine uptake and clinical responses with Needle-Free PharmaJet Precision Delivery Systems, the presentation will discuss the safety, immunogenicity and clinical efficacy of DNA vaccines when administered using needle-free precision delivery systems (PDS) and alternative methods including electroporation, gene gun, and needle and syringe (N/S) delivery.
Topline results of the analysis showed that DNA vaccines delivered needle-free tend to induce immunogenicity that is non-inferior to electroporation. DNA vaccines delivered needle-free also tend to elicit improved immunogenicity compared with N/S, according to the authors of the publication. In addition, compared with electroporation and with N/S, needle-free PDS provide a wider dispersion pattern of the DNA vaccine within tissues and more precise, efficient delivery into cells.1
“When it comes to administering vaccines, two of the most important clinical outcomes are increased immunogenicity and enhanced protection from disease,” said Erin Spiegel, Ph.D, Vice President Clinical and Regulatory Affairs, PharmaJet. “This comprehensive scientific review clearly shows that needle-free delivery of DNA vaccines can accomplish both outcomes, outperforming alternative methods. The data associated with needle-free precision delivery systems demonstrate this technology platform can be expected to enhance vaccine immune response.” She added, “We are committed to continue investigating the benefits of our precision delivery systems when combined with DNA or other vaccine platforms.”
The April 5 World Vaccine Congress 2023 presentation will be based on an article sponsored by PharmaJet that was recently published in the journal, Vaccines, in a paper titled Improved DNA Vaccine Delivery with Needle-Free Injection Systems.
Refer to Instructions for Use to ensure safe injections and to review risks.
- Ledesma-Feliciano, C et al, Improved DNA Vaccine Delivery with Needle-free Injection Systems, Vaccines 2023, 11(2), 280; 28 January 2023
About DNA Vaccines
DNA vaccines exhibit inherent advantages compared with other vaccine types, and therefore hold great promise in combating any number of emerging infectious diseases. These advantages include a more favorable clinical safety profile, the ability to be developed at an accelerated rate in the laboratory and to be manufactured quickly and relatively easily compared to other vaccine platforms. The thermostability profile of DNA vaccines allows for ease of storage. Different routes of administration of DNA vaccines produce varying effects on the vaccine’s clinical features, though. For example, needle and syringe delivery has been shown to produce inadequate immunogenicity arising from inefficient uptake of the DNA at the cellular level. Multiple techniques have been employed to boost the immunogenicity and protective efficacy of DNA vaccines including physical, electrical, and chemical delivery methods, molecular and traditional adjuvants, and genetic sequence enhancements.
About Needle-Free Precision Delivery Systems (PDS)
The PharmaJet Tropis® PDS was selected in 2021 as the exclusive delivery system for the world’s first DNA vaccine approved for administration in humans: ZyCoV-D. Zydus Lifesciences Limited, ZyCoV-D license holder, achieved restricted use approval granted by the Drug Controller General of India for that ground-breaking vaccine. Zydus Lifesciences selected Tropis® PDS over traditional DNA vaccine delivery methods based on pre-clinical and clinical study results that indicated needle-free precision delivery increased the clinical effectiveness of ZyCoV-D compared with delivery by needle and syringe.
Additional indications for which the PharmaJet PDS have recently been used to deliver DNA vaccines include COVID-19, HIV, Zika, influenza, poxvirus, hantavirus, and dengue viral infections.
The PharmaJet vision is to enable greater access to life-saving vaccines and pharmaceuticals globally. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information visit https://pharmajet.com. Follow us on LinkedIn.